ODDB.org: Open Drug Database | Drugs

Infanrix DTPa-IPV+Hib, Pulver und Suspension zur Herstellung einer Injektionssuspension -

Swissmedic Key	00619003	Registration Holder	GlaxoSmithKline AG
Name	Infanrix DTPa-IPV+Hib, Pulver und Suspension zur Herstellung einer Injektionssuspension	Date of registration	29.09.1998
		Introduction of Sequence	29.09.1998
ATC-Classification	Diphtheria-Haemophilus Influenzae B-Pertussis-Poliomyelitis-Tetanus (J07CA06)	Revision date
WHO	WHO-DDD	Valid until
Index Therapeuticus (BSV)	08.08.	Show package size
Index Therapeuticus (Swissmedic)	08.08.	Description
Swissmedic categorie.	B
SL Eintrag	Yes	Indication
Information for professionals	IP	Consumer information
Ex-factory-Price	34.32	Limitation	Yes
Limitation text

Deductible	10 %	Consumer price	53.75
Feedback	FB
GTIN	7680006190030	Medication Code	Impfstoffe
Pharmacode		Disponibility

Composition

I) DTPa-IPV: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, polysorbatum 80, formaldehydum. II) Hib: polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, lactosum, pro praeparatione. I) et II) corresp. DTPa-IPV + Hib: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, lactosum, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, polysorbatum 80, formaldehydum.

Packungsbestandteile

Label

Galenic Form

Injection suspension

Excipiens

BAG: Active Agent	Dose
	25 mcg
	10 mcg
	8 mcg

	25 mcg

	40 UI
	8 UI
	32 UI

Inactive agents	Dose
	10 µg

	20752

correspond

I) et II) corresp. DTPa-IPV + Hib: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, aluminium ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum, lactosum, medium 199, residui: polysorbatum 80 et formaldehydum et neomycini sulfas et polymyxini B sulfas, aqua q.s. ad suspensionem pro 0.5 ml

BAG: Active Agent	Dose
	25 mcg
	10 mcg
	8 mcg

	25 mcg

	40 UI
	8 UI
	32 UI

Label

Galenic Form

Excipiens

Active Agent	Dose
	25µg / 0.5ml
	8µg / 0.5ml
	30U.I. / 0.5ml
	25µg / 0.5ml
	40U.I. / 0.5ml
	40U. / 0.5ml
	8U. / 0.5ml
	32U. / 0.5ml

BAG: Active Agent	Dose
	25 mcg
	10 mcg
	8 mcg

	25 mcg

	40 UI
	8 UI
	32 UI

Inactive agents	Dose
Alumine	0.5mg / 0.5ml
	199
Sodium Chloride
Neomycin Sulfate
Polymyxine b Sulfate

Source

Data was imported : 05.01.2024 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :

2025	©ywesee GmbH